Down-regulation of BRCA1 in chronite pancreatitis and sporadic pancreatic adenocarcinoma

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3780-3787

  Beger, Carmela ^a   Ramadani, Marco ^b   Meyer, Stephan ^a   Leder, Gerd ^c   Krüger, Martin ^a   Welte, Karl ^a   Gansauge, Frank ^b   Beger, Hans G ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ALCOHOLIC PANCREATITIS; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHRONIC PANCREATITIS; DOWN REGULATION; FAMILY STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC RISK; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; DOWN-REGULATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK; RNA; TIME FACTORS; TREATMENT OUTCOME;

EID: 2542590280     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0992-3     Document Type: Article

References (36)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (Wash DC) 1994;266:66-71.
2. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature (Lond) 1995;378:789-92.
3. Sourvinos G, Spandidos DA. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem Biophys Res Commun 1998;245:75-80.
4. Wilson CA, Ramos L, Villasenor MR, et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999;21:236-40.
5. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995;9:444-50.
6. Bieche I, Nogues C, Lidereau R. Overexpression of BRCA2 gene in sporadic breast tumours. Oncogene 1999;18:5232-8.
7. Egawa C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with clinicopathological characteristics. Jpn J Cancer Res 2001;92:624-30.
8. Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001;10:705-13.
9. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-82.
10. Cancer Research Campaign (CRC) Genetic Epidemiology Unit. Cancer risks in BRCA2 mutation carriers. The breast cancer linkage consortium. J Natl Cancer Inst (Bethesda) 1999;91:1310-6.
11. Thompson D, Easton DF, and Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst (Bethesda) 2002;94:1344-5.
12. Wilson CA, Payton MN, Elliott GS, et al. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene 1997;14:1-16.
13. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002;62:3789-93.
14. Chappuis PO, Ghadirian P, Foulkes WD. The role of genetic factors in the etiology of pancreatic adenocarcinoma: an update. Cancer Investig 2001;19:65-75.
15. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst (Bethesda) 2003;95:214-21.
16. Moll U, Lau R, Sypes MA, Gupta MM, Anderson CW. DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant tissues. Oncogene 1999;18:3114-26.
17. Thakur S, Zhang HB, Peng Y, et al. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol 1997;17:444-52.
18. Gudjonsson B. Cancer of the pancreas: critical analysis of costs, results of resections and the need for standardized reporting. J Am Coll Surg 1995;181:483-503.
19. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993;328:1433-7.
20. Talamini G, Falconi M, Bassi C, et al. Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol 1999;94:1253-60.
21. Kern SE. Molecular genetics of adenocarcinoma of the pancreas. In: Cameron J, editor. Pancreatic cancer. Hamilton, Ontario, Canada: B. C. Decker Inc.; 2001. p. 13-24.
22. Wang H, Zeng ZC, Bui TA, et al. Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2. Cancer Res 2001;61:270-7.
23. Maacke H, Jost K, Opitz S, et al. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 2000;19:2791-5.
24. Yamamoto H, Itoh F, Nakamura H, et al. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res 2001;61:3139-44.
25. Andren-Sandberg A, Hoem D, Backman PL. Other risk factors for pancreatic cancer: hormonal aspects. Ann Oncol 1999;10:131-5.
26. Robles-Diaz G, Duarte-Rojo A. Pancreas: a sex steroid-dependent tissue. Isr Med Assoc J 2001;3:364-8.
27. Hollande E, Fanjul M, Houti N, Faye JC, Courriere P. Expression of estrogen receptors during growth of human pancreatic adenocarcinoma cells (Capan-1)-relationship with differentiation. In Vitro Cell Dev Biol Anim 1998;34:593-9.
28. Iwao K, Miyoshi Y, Ooka M, et al. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in human pancreatic cancers by real-time polymerase chain reaction. Cancer Lett 2001;170:91-7.
29. Wang Y, Cortez D, Yazdi P, et al. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000;14:927-39.
30. Wang Q, Zhang H, Fishel R, Greene MI. BRCA1 and cell signaling. Oncogene 2000;19:6152-8.
31. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
32. Scarpa A, Capelli P, Mukai K, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993;42:1534-43.
33. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (Wash DC) 1996;271:350-3.
34. Ruggeri BA, Huang L, Berger D, et al. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer (Phila) 1997;79:700-16.
35. Grunewald K, Lyons J, Frohlich A, et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43:1037-41.
36. Hiyama E, Kodama T, Shinbara K, et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 1997;57:326-31.